Page 134 - IJB-9-4

International Journal of Bioprinting 3D bioprinted models in pediatric tumors

Data acquisition: Colin H. Quinn, Andee M. Beierle, Janet tumors versus neuroblastoma in children and young adults:
R. Julson, Michael E. Erwin, Hasan Alrefai, Hooper R. Nine standard SEER registries, 1975-2006. Pediatr Blood
Markert, Sara Claire Hutchins, Laura V. Bownes Cancer, 56(1):50–57.
Formal analysis: Colin H. Quinn, Michael E. Erwin, https://doi.org/10.1002/pbc.22559
Hooper R. Markert, Elizabeth Mroczek-Musulman 4. LeSavage BL, Suhar RA, Broguiere N, et al., 2022, Next-
Funding acquisition: Christopher D. Willey, Elizabeth A. generation cancer organoids. Nat Mater, 21(2):143–159.
Beierle
Investigation: Colin H. Quinn, Andee M. Beierle, Janet R. https://doi.org/10.1038/s41563-021-01057-5
Julson, Michael E. Erwin, Hasan Alrefai, Hooper R. 5. Kang Y, Datta P, Shanmughapriya S, et al., 2020, 3D
Markert, Sara Claire Hutchins, Laura V. Bownes bioprinting of tumor models for cancer research. ACS Appl
Resources: Jerry E. Stewart, Jamie M. Aye, Patricia H. Hicks, Bio Mater, 3(9):5552–5573.
Karina J. Yoon, Christopher D. Willey, Elizabeth A. https://doi.org/10.1021/acsabm.0c00791
Beierle 6. Zhuang P, Chiang YH, Fernanda MS, et al., 2021, Using
Supervision: Elizabeth A. Beierle spheroids as building blocks towards 3D bioprinting of
Writing – original draft: Colin H. Quinn, Andee M. Beierle, tumor microenvironment. Int J Bioprint, 7(4):444.
Elizabeth A. Beierle https://doi.org/10.18063/ijb.v7i4.444
Writing – review & editing: Colin H. Quinn, Andee M.
Beierle, Elizabeth A. Beierle 7. Neufeld L, Yeini E, Reisman N, et al., 2021, Microengineered
perfusable 3D-bioprinted glioblastoma model for in
Ethics approval and consent to participate vivo mimicry of tumor microenvironment. Sci Adv,
7(34):eabi9119.
Tumors were obtained as previously described under the https://doi.org/10.1126/sciadv.abi9119
University of Alabama at Birmingham (UAB) Institutional 8. Langer EM, Allen-Petersen BL, King SM, et al.,
Review Board (IRB)-approved protocol (IRB 130627006) 2019, Modeling tumor phenotypes in vitro with
and in accordance with the Declaration of Helsinki as three-dimensional bioprinting. Cell Rep, 26(3):
well as the guidelines of the National Institutes of Health. 608–623 e6.
Informed consent was obtained from all guardians and https://doi.org/10.1016/j.celrep.2018.12.090
assent from patients where appropriate prior to study
enrollment. 9. Stafman LL, Williams AP, Marayati R, et al., 2019, Focal
adhesion kinase inhibition contributes to tumor cell survival
Consent for publication and motility in neuroblastoma patient-derived xenografts. Sci
Rep, 9(1):13259.
Informed consent was obtained from all guardians and https://doi.org/10.1038/s41598-019-49853-z
assent from patients where appropriate to publish their 10. Quinn CH, Beierle AM, Williams AP, et al., 2021,
data in this study.
Downregulation of PDGFRss signaling overcomes crizotinib
resistance in a TYRO3 and ALK mutated neuroendocrine-
Availability of data like tumor. Transl Oncol, 14(7):101099.

The data from these studies are available from the https://doi.org/10.1016/j.tranon.2021.101099
corresponding author, Dr. Elizabeth A. Beierle, upon 11. Marayati R, Bownes LV, Quinn CH, et al., 2021, Novel
reasonable request. second-generation rexinoid induces growth arrest and
reduces cancer cell stemness in human neuroblastoma
References patient-derived xenografts. J Pediatr Surg, 56(6):1165–1173.
https://doi.org/10.1016/j.jpedsurg.2021.02.041
1. Siegel RL, Miller KD, Fuchs HE, et al., 2022, Cancer statistics.
CA Cancer J Clin, 72(1):7–33. 12. Stafman LL, Mruthyunjayappa S, Waters AM, et al., 2018,
Targeting PIM kinase as a therapeutic strategy in human
https://doi.org/10.3322/caac.21708 hepatoblastoma. Oncotarget, 9(32):22665–22679.
2. Colon NC, Chung DH, 2011, Neuroblastoma. Adv Pediatr, https://doi.org/10.18632/oncotarget.25205
58(1):297–311.
13. Quinn CH, Beierle AM, Hutchins SC, et al., 2022, Targeting
https://doi.org/10.1016/j.yapd.2011.03.011 high-risk neuroblastoma patient-derived xenografts with
3. Navalkele P, O’Dorisio MS, O’Dorisio TM, et al., 2011, oncolytic virotherapy. Cancers (Basel), 14(3):762.
Incidence, survival, and prevalence of neuroendocrine https://doi.org/10.3390/cancers14030762

Volume 9 Issue 4 (2023) 126 https://doi.org/10.18063/ijb.723